Related Experiment Video

Updated: May 21, 2026

Multiomics Analysis of TMEM200A as a Pan-Cancer Biomarker
07:47

Multiomics Analysis of TMEM200A as a Pan-Cancer Biomarker

Published on: September 15, 2023

Stathmin 1: a protein with many tasks. New biomarker and potential target in cancer

John Nemunaitis

    Expert Opinion on Therapeutic Targets
    |June 13, 2012
    PubMed

    Insights

    Targeting Stathmin 1 (STMN1), a protein vital for cancer cell survival and microtubule polymerization, offers a promising therapeutic strategy. Disrupting STMN1 modulation effectively impacts cancer progression and survival rates.

    Area of Science:

    • Oncology
    • Cell Biology
    • Pharmacology

    Background:

    • Stathmin 1 (STMN1) is a key protein regulating microtubule dynamics, essential for cancer cell proliferation and survival.
    • Microtubule instability is a hallmark of cancer, making STMN1 a critical target for therapeutic intervention.

    Discussion:

    • Targeted therapeutics designed to inhibit STMN1 function represent a novel approach in cancer treatment.
    • Disruption of STMN1 modulation can lead to mitotic arrest and apoptosis in cancer cells.
    • Understanding STMN1's role in microtubule polymerization is crucial for developing effective anti-cancer drugs.

    Key Insights:

    • STMN1 is indispensable for the survival of various cancer types.
    • Therapeutic strategies focusing on STMN1 inhibition show significant potential in preclinical models.
    • Modulating STMN1 offers a pathway to overcome therapeutic resistance in cancer.

    Outlook:

    • Further research into STMN1-targeted therapies could lead to new treatment options for difficult-to-treat cancers.
    • Combination therapies involving STMN1 inhibitors may enhance treatment efficacy.
    • Clinical trials are warranted to evaluate the safety and effectiveness of STMN1-targeting drugs in cancer patients.

    More Related Videos

    A Streamlined Approach for Mass Spectrometry-Based Proteomics Using Selected Tissue Regions09:00

    A Streamlined Approach for Mass Spectrometry-Based Proteomics Using Selected Tissue Regions

    Published on: April 18, 2025

    Using a GFP-tagged TMEM184A Construct for Confirmation of Heparin Receptor Identity10:41

    Using a GFP-tagged TMEM184A Construct for Confirmation of Heparin Receptor Identity

    Published on: February 17, 2017

    Related Concept Videos

    Destabilization of Microtubules01:45

    Destabilization of Microtubules

    The destabilization of microtubules can occur during different stages of the microtubule lifecycle, such as nucleation or elongation. It can take place at either end of the microtubule or in the microtubule lattices as a whole. The lifespan of individual microtubules within a cell varies according to the cell type and stage of the cell cycle. During interphase, the lifespan of the microtubule is about 30 minutes, while during cell division, it is about 15 minutes. In axonal microtubules of...
    Drugs that Stabilize Microtubules01:15

    Drugs that Stabilize Microtubules

    Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
    mTOR Signaling and Cancer Progression03:03

    mTOR Signaling and Cancer Progression

    The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
    The mTOR pathway or the...
    Targeted Cancer Therapies02:57

    Targeted Cancer Therapies

    The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
    There are several types of targeted therapies against specific...